^
    Back
    Association details:
    Biomarker:EGFR mutation + TP53 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug Class:EGFR inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: B - Late Trials
    Source:
    ELCC 2022
    Title:

    67P-Distinct concomitant genetic alterations in EGFR-mutant non-small cell lung cancer patients with brain metastases

    Published date:
    03/23/2022
    Excerpt:
    A total of 2657 NSCLC patients with brain metastases were screened and 737 harboring EGFR mutation, among 73 patients with NGS data, all receiving EGFR TKI treatment...Concomitant genetic alterations were significantly associated with reduced OS (23.2 months vs NR, P= 0.016). Especially, TP53 mutation (HR = 1.8, 95%CI:1.0-3.2) and EGFR amplification (HR = 2.5, 95% CI:1.2-5.6) were associated with significantly worse OS....
    DOI:
    https://doi.org/10.1016/j.annonc.2022.02.076
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Thorac Cancer
    Title:

    Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer

    Published date:
    07/06/2023
    Excerpt:
    A single-center retrospective study was conducted to evaluate the influence of PD-L1 expression on the efficacy of EGFR-TKIs for NSCLC patients with EGFR mutation....Patients with concurrent TP53 mutation had shorter PFS (p = 0.039) and the patients harboring both mutant TP53 and positive PD-L1 had the shortest PFS (p = 0.006).
    DOI:
    10.1111/1759-7714.15021
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    BMC Cancer
    Title:

    Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non–small-cell lung cancer with an EGFR/TP53 co-mutation

    Published date:
    12/12/2022
    Excerpt:
    CONTRADICTING EVIDENCE: Our study indicates that EGFR-TKIs combined with chemotherapy could significantly improve the ORR and TTP of advanced NSCLC patients with an EGFR/TP53 co-mutation.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.1186/s12885-022-10391-z
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Research Square
    Title:

    Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: A real- world study

    Published date:
    11/30/2022
    Excerpt:
    CONTRADICTING EVIDENCE: The present study aims to compare the benefits of EGFR-TKIs and its combination with antiangiogenic drugs or chemotherapy in patients with NSCLC harboring EGFR and TP53 co-mutation in a real-life setting....Combination therapy had a higher efficacy than EGFR-TKI alone for patients with NSCLC having concomitant EGFR and TP53 mutation.
    Secondary therapy:
    Chemotherapy
    DOI:
    https://doi.org/10.21203/rs.3.rs-2247421/v1
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Lung Cancer
    Title:

    A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population

    Published date:
    11/09/2022
    Excerpt:
    A cohort of 111 patients with advanced NSCLC harboring EGFR-sensitive mutations detected by PCR was analyzed in 5 Latin American oncological centers from January 2019 to December 2020. All eligible patients received upfront therapy with EGFR-TKI….patients with a TP53 mutation had a shorter PFS, 13.6 (95 %CI: 10.7-15.5) vs 19.2 months (95 %CI: 12.8-NR); in wild type TP53 [HR 2.01 (95 %CI: 1.18-3.74) p = 0.12].
    DOI:
    10.1016/j.lungcan.2022.11.002